AbbVie Inc. (ABBV) Stock Price & Analysis
AbbVie Inc. (ABBV) closed at USD 285.19 on Thursday, October 22, 2026, up 0.14% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 284.8; the Oct 22, 2026 session ranged USD 278.01–285.74 on volume of 6,172,149 shares. Market capitalization is $503.96B, with a 52-week range of USD 190.75–291.4 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.
Also available as compact Markdown for AI agents: nexqual.com/ABBV.md
Key facts (ABBV)
- Last four reported quarters (through Jun 30, 2026): revenue $64.4B, net income $6.31B (9.8% margin), free cash flow $18.2B (SEC filings).
- Valuation: P/E 79.9x (avg 75.3x at the last 3 fiscal year-ends).
- Earnings quality: non-operating income -$5.49B vs operating income $16.9B over the last four quarters; P/E excluding non-operating income ≈48.9x (estimate: non-operating income taxed at the company's 27.4% effective rate).
- 7 of 80 tracked superinvestors hold ABBV (13F, Q2 2026 (1 investor on Q3 2026, filed early)): 0 new, 0 added, 5 reduced, 2 unchanged.
- Analysts: Buy (mean 2.00 on a 1–5 scale) (30 analysts), mean target USD 284.79 (range 200–328).
- Total return with dividends: 1Y +28.7% vs S&P 500 +14.9%; 5Y +212.1% vs S&P 500 +80.3%.
- Next earnings: 2026-10-30, EPS estimate USD 3.78, revenue estimate $17.3B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ABBV)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B | $64.4B |
| Gross profit | $38.8B | $40.6B | $33.9B | $39.4B | $43.0B | — |
| Operating income | $17.9B | $18.1B | $12.8B | $9.14B | $15.1B | $16.9B |
| Net income | $11.5B | $11.8B | $4.86B | $4.28B | $4.23B | $6.31B |
| EPS (diluted) | $6.45 | $6.63 | $2.72 | $2.39 | $2.36 | — |
| Free cash flow | $22.0B | $24.2B | $22.1B | $17.8B | $17.8B | $18.2B |
| Gross margin | 69.0% | 70.0% | 62.4% | 70.0% | 70.2% | — |
| Operating margin | 31.9% | 31.2% | 23.5% | 16.2% | 24.6% | 26.2% |
| Net margin | 20.5% | 20.4% | 9.0% | 7.6% | 6.9% | 9.8% |
| Revenue growth | +22.7% | +3.3% | -6.4% | +3.7% | +8.6% | — |
| Cash + short-term investments | $9.83B | $9.23B | $12.8B | $5.55B | $5.26B | — |
| Total debt | $76.0B | $63.1B | $59.2B | $66.8B | $67.0B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (ABBV)
P/E 79.9x · P/E ex non-operating (est.) ≈48.9x · P/S 7.8x · P/FCF 27.7x · FCF yield 3.61% · Earnings yield 1.25% · Dividend yield (paid, TTM) 2.38% · Buyback yield (TTM) 0.30%
P/E at fiscal year-ends: Dec 2025 95.9x, Dec 2024 73.6x, Dec 2023 56.5x.
Superinvestors (SEC 13F-HR, Q2 2026) (ABBV)
7 of 80 tracked investors hold ABBV (1 investor on Q3 2026, filed early). Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change | Quarter |
|---|---|---|---|---|---|
| Torray Funds | 2.80% | $20.8M | Reduced -11.7% | Q2 2026 | |
| David Katz | Matrix Asset Advisors | 0.73% | $8.9M | Reduced -13.2% | Q3 2026 |
| Mairs & Power | Mairs & Power Funds | 0.10% | $11.2M | Reduced -1.4% | Q2 2026 |
| Jensen Investment Management | 0.07% | $2.8M | Reduced -0.7% | Q2 2026 | |
| Thomas Russo | Gardner Russo & Quinn | 0.03% | $3.1M | Unchanged | Q2 2026 |
| Dodge & Cox Funds | Dodge & Cox | <0.01% | $2.6M | Unchanged | Q2 2026 |
| Bill Nygren | Oakmark Funds | <0.01% | $609K | Reduced -9.8% | Q2 2026 |
Analysts (ABBV)
Consensus Buy (mean 2.00 on a 1–5 scale), 30 analysts; mean target USD 284.79 (low 200, high 328).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Barclays | Target raised | Overweight | $300 → $325 |
| 2026-10-13 | RBC Capital | Reiterated | Outperform | $280 |
| 2026-10-09 | UBS | Target raised | Neutral | $260 → $275 |
| 2026-10-09 | Guggenheim | Reiterated | Buy | $288 |
| 2026-10-08 | JP Morgan | Target raised | Overweight | $285 → $300 |
| 2026-10-08 | Cantor Fitzgerald | Target raised | Overweight | $285 → $290 |
| 2026-10-07 | Morgan Stanley | Target raised | Overweight | $296 → $310 |
| 2026-10-06 | Scotiabank | Target raised | Sector Outperform | $280 → $320 |
| 2026-09-10 | HSBC | Target raised | Buy | $300 → $315 |
| 2026-08-20 | Piper Sandler | Target raised | Overweight | $298 → $303 |
| 2026-08-17 | Wells Fargo | Target raised | Overweight | $295 → $300 |
| 2026-08-13 | Wolfe Research | Upgrade | Peer Perform → Outperform | $300 |
Total return (dividends reinvested) (ABBV)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +28.7% | +212.1% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +28.8% | +25.5% |
| Volatility (annualized) | 25.8% | 24.9% |
| Max drawdown | -15.7% (Mar 2026→Apr 2026) | -21.9% (Apr 2022→Sep 2022) |
Companies that name ABBV in their SEC reports
| Relationship to ABBV | Company | Filing | Sentence |
|---|---|---|---|
| competitor | Alzamend Neuro, Inc. (ALZN) | 10-K Jul 22, 2026 | “Our potential competitors include, without limitation, large healthcare companies, such as AbbVie, Axesome Therapeutics, Inc., Biogen” |
| customer | TAKEDA PHARMACEUTICAL CO LTD (TAK) | 20-F Jun 17, 2026 | “The corrective actions resulted in a temporary supply shortage of Leuprorelin, a product which we supply to AbbVie, Inc. ("AbbVie") pursuant to a supply agreement.” |
| competitor | Prestige Consumer Healthcare Inc. (PBH) | 10-K May 14, 2026 | “Our branded competitors include, among others, AbbVie Inc., Alcon, Bausch + Lomb, Bayer AG, Combe, Compass Diversified, Haleon plc, Kenvue, Mondelez International, Reckitt Benckiser Group plc, Opella, Scholl's Wellness Company, Sunstar Group, The Procter & Gamble Company and Unilever.” |
| competitor | ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) | 20-F Apr 29, 2026 | “candidates that can be competitive, including AbbVie, which is currently marketing venetoclax.” |
| competitor | RedHill Biopharma Ltd. (RDHL) | 20-F Apr 27, 2026 | “If approved, RHB-102 (Bekinda®) will also compete with several other prescription drugs indicated for the treatment of IBS-D, including Xifaxan® (rifaximin), marketed in the U.S. by Salix Pharmaceuticals, and Viberzi® (eluxadoline), marketed in the U.S. by Allergan plc., now AbbVie Inc. Additional prescription drugs and over-the-counter products may also be used to manage symptoms of IBS-D and may represent additi…” |
| partner | Inventiva S.A. (IVA) | 20-F Apr 8, 2026 | “In addition, we previously entered into a collaboration with AbbVie for the development of cedirogant, which ended in October 2022 when AbbVie decided to stop the development of cedirogant following the analysis of a nonclinical toxicology study.” |
| partner | NovaBridge Biosciences (NBP) | 20-F Apr 7, 2026 | “On August 15, 2022, we and AbbVie Global Enterprises Ltd. (as an assignee of AbbVie) entered into an amendment to the original licensing and collaboration agreement.” |
| competitor | HCW Biologics Inc. (HCWB) | 10-K Mar 31, 2026 | “The oncology T‑cell engager landscape is highly competitive, with established and emerging programs from biotech and pharmaceutical companies, including AbbVie, BMS, Sanofi, Lilly, Amgen's bispecifics, Genmab/Daiichi Sankyo's multispecific platforms, and numerous CD3‑engager programs in development targeting both hematologic and solid tumors.” |
| competitor | Alvotech (ALVO) | 20-F Mar 31, 2026 | “For example, in the market for AVT02, our biosimilar to Humira (adalimumab), we compete against AbbVie (the originator), Amgen, Boehringer Ingelheim GmbH, Biocon, Celltrion, Fresenius Kabi, Pfizer, Samsung Bioepis, Coherus, and Sandoz; in the market for AVT04, our biosimilar to Stelara (ustekinumab), we compete against Janssen (the originator), Amgen, Celltrion, Bio-Thera, Formycon, Dong-A/Meiji Seika, Samsung Bio…” |
| competitor | Aptevo Therapeutics Inc. (APVO) | 10-K Mar 26, 2026 | “We believe that our most significant competitors in the oncology market include: AbbVie Inc., Affimed, ALX Oncology Holdings Inc., Amgen Inc., Arcellx, AstraZeneca, AvenCell Therapeutics, Inc., BioNTech, Bio-Path, Bristol Myers Squibb, Cellectis, Creative Biolabs, Faron Pharma, F-star Therapeutics, Genentech Inc. (a subsidiary of F.” |
| partner | Lakefront Biotherapeutics NV (LKFT) | 20-F Mar 26, 2026 | “In this role, he oversaw complex mergers, acquisitions, licensing, and collaborations, including AbbVie's landmark $63 billion acquisition of Allergan PLC and numerous high-profile partnerships with companies such as Boehringer Ingelheim and Genmab.” |
| competitor | LB PHARMACEUTICALS INC (LBRX) | 10-K Mar 26, 2026 | “In bipolar depression, we believe LB-102, if approved, would compete with several currently approved therapeutics, including: Vraylar (marketed by AbbVie Inc.);” |
| competitor | Rani Therapeutics Holdings, Inc. (RANI) | 10-K Mar 26, 2026 | “Broadly speaking, we will face competition from current and future (generic or biosimilar) manufacturers of the branded injectable versions of our pipeline drugs, manufacturers such as AbbVie Inc., Eli Lilly and Company, and Johnson & Johnson Innovative Medicine.” |
| partner | CollPlant Biotechnologies Ltd (CLGN) | 20-F Mar 26, 2026 | “into the AbbVie Development Agreement with Allergan, an AbbVie company, pursuant to which dermal and soft tissue filler products are being” |
| competitor | SpyGlass Pharma, Inc. (SGP) | 10-K Mar 26, 2026 | “For example, we compete with alternative glaucoma surgical device and ophthalmic laser companies such as Alcon, Allergan (AbbVie), Bausch & Lomb, Glaukos, and Johnson & Johnson, as well as pharmaceutical competitors such as Alcon, Allergan (AbbVie), Astellas, Genentech (Roche) and Regeneron.” |
ABBV analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $3.78 | $3.85 | -1.7% | $17.35B | 21 |
| Next quarter (ends Dec 2026) | $3.89 | $4.00 | -2.9% | $18.30B | 19 |
| Current fiscal year (ends Dec 2026) | $13.96 | $14.15 | -1.4% | $67.63B | 27 |
| Next fiscal year (ends Dec 2027) | $16.20 | $16.33 | -0.8% | $73.59B | 25 |
Key Statistics (as of October 23, 2026 at 09:26 UTC)
| Price | USD 285.19 |
|---|---|
| Change | ▲ 0.14% (up) |
| Previous Close | USD 284.8 |
| Open | USD 284.57 |
| Day Range | USD 278.01 – 285.74 |
| 52-Week Range | USD 190.75 – 291.4 |
| Volume | 6,172,149 shares |
| Market Cap | $503.96B |
| Exchange | NYQ |
Technical Analysis (ABBV)
Nexqual's technical model rates ABBV "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 65.78 (neutral) |
| vs SMA50 | Above (USD 265.43) |
| MACD | 6.59 (positive) |
Analyst Ratings (ABBV)
Wall Street analysts rate ABBV "Buy" based on 30 analysts, with a mean price target of USD 284.79 (range USD 200–328), per Nexqual as of October 23, 2026 at 09:26 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 30 |
| Mean Target | USD 284.79 |
| High Target | USD 328 |
| Low Target | USD 200 |
| Buy / Hold / Sell | 24 / 5 / 1 |
Earnings (ABBV)
| Next Earnings Date | 2026-10-30 |
|---|---|
| EPS Estimate | USD 3.78 |
| Revenue Estimate | $17.35B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 3.65 vs est 3.61 ▲ beat |
| 2026-03-31 | USD 2.65 vs est 2.67 ▼ miss |
| 2025-12-31 | USD 2.71 vs est 2.65 ▲ beat |
| 2025-09-30 | USD 1.86 vs est 1.78 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financials & Fundamentals (ABBV)
| Total Revenue | $64.39B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +10.20% |
| Gross Margin | +72.79% |
| Operating Margin | +40.03% |
| Profit Margin | +9.80% |
| Current Ratio | 0.81 |
| Total Cash | $6.57B |
| Total Debt | $70.88B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $18.21B (28.3% of revenue) |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Financial Health Score (ABBV)
Nexqual rates AbbVie Inc.'s overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:26 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 73%, operating 40% (last 12 months) |
| Balance Sheet | Mixed — $5.26B cash and investments vs $67.0B debt (Dec 2025, SEC) |
| Cash Flow | Strong — FCF $18.2B (last 4 quarters to Jun 2026, SEC), 28% margin |
| Efficiency | Mixed — No data |
Ownership (ABBV)
| Insider Ownership | +0.11% |
|---|---|
| Institutional Ownership | +77.35% |
| Shares Outstanding | 1.77B |
| Float | 1.76B |
| Short % of Float | +1.02% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Leadership (ABBV)
AbbVie Inc. is led by Robert A. Michael, CEO & Chairman of the Board, per Nexqual as of October 23, 2026 at 09:26 UTC.
| CEO & Chairman of the Board | Robert A. Michael |
|---|---|
| Executive VP & CFO | Scott T. Reents |
| Executive VP & COO | Azita Saleki |
| Executive VP of Research & Development and Chief Scientific Officer | Roopal B. Thakkar |
| Senior Vice President of Investor Relations | Elizabeth Shea |
Major Backers & Investors (ABBV)
Notable institutional backers of AbbVie Inc. include JPMorgan, Morgan Stanley, Capital Group, according to Nexqual as of October 23, 2026 at 09:26 UTC.
Active Investors
| Investor | Stake |
|---|---|
| JPMorgan | 2.71% |
| Morgan Stanley | 2.2% |
| Capital Group | 1.7% |
| NORGES BANK | 1.45% |
| Fidelity | 1.3% |
| Bank of America Corporation | 1.2% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.27% |
| BlackRock | 8.46% |
| State Street | 4.67% |
| Geode Capital | 2.66% |
Source: Nexqual, October 23, 2026 at 09:26 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| JNJ | Johnson & Johnson | USD 267.61 | ▲ 3.81% |
| MRK | Merck & Company, Inc. | USD 147.24 | ▼ 1.76% |
| NVS | Novartis AG | USD 156.27 | ▲ 1.52% |
| AZN | AstraZeneca PLC | USD 172.57 | ▲ 2.45% |
| AMGN | Amgen Inc. | USD 447.28 | ▲ 2.04% |
| LLY | Eli Lilly and Company | USD 1,306.69 | ▲ 2.83% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt